A Novel Mechanism of EML4-ALK Rearrangement Mediated by Chromothripsis in a Patient-Derived Cell Line
- 1 November 2014
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 9 (11) , 1638-1646
Abstract
No abstract availableKeywords
Funding Information
- Princess Takamatsu Cancer Research Fund
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Health, Labour and Welfare
- Chugai Pharmaceutical
- Japan Society for the Promotion of Science
- Smoking Research Foundation
This publication has 34 references indexed in Scilit:
- Characterization of Rearrangements Involving the ALK Gene Reveals a Novel Truncated Form Associated with Tumor Aggressiveness in NeuroblastomaCancer Research, 2013
- Subgroup-specific structural variation across 1,000 medulloblastoma genomesNature, 2012
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung CancersScience Translational Medicine, 2012
- Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cellsBritish Journal of Cancer, 2012
- Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 MutationsCell, 2012
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKProceedings of the National Academy of Sciences, 2011
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR InhibitorsScience Translational Medicine, 2011
- Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer DevelopmentCell, 2011
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- EML4-ALKFusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung CancerClinical Cancer Research, 2008